Aug
12
Mon
2013
Invited Talk: A Far- Western Clinical Proteomics Approach to Detect Molecules of Clinical and Pathological Significance in the Neurodegenerative Disease Multiple Sclerosis @ Amriteshwari Hall
Aug 12 @ 11:27 am – 11:50 am

krishnakumarKrishnakumar Menon, Ph.D.
Associate Professor, Centre for Nanosciences & Molecular Medicine, Amrita University, Kochi, India


A Far-Western Clinical Proteomics Approach to Detect Molecules of Clinical and Pathological Significance in the Neurodegenerative Disease Multiple Sclerosis.

Multiple Sclerosis (MS), an autoimmune neurodegenerative disorder of the central nervous system. The disease affects young adults at their prime age leading to severe debilitation over several years.  Despite advances in MS research, the cause of the disease remains elusive. Thus, our objective is to identify novel molecules of pathological and diagnostic significance important in the understanding, early diagnosis and treatment of MS. Biological fluids such as cerebrospinal fluid (CSF), that bathe the brain serve as a potential source for the identification of pathologically significant autoantibody reactivity in MS.  In this regard, we report the development of an unbiased clinical proteomics approach for the detection of reactive CSF molecules that target brain proteins from patients with MS. Proteins of myelin and myelin-axolemmal complexes were separated by two-dimensional gel electrophoresis, blotted onto membranes and probed separately with biotinylated unprocessed CSF samples. Protein spots that reacted specifically to MS-CSF’s were further analyzed by matrix assisted laser desorption ionization-time-of-flight time-of-flight mass spectrometry. In addition to previously reported proteins found in MS, we have identified several additional molecules involved in mitochondrial and energy metabolism, myelin gene expression and/or cytoskeletal organization. Among these identified molecules, the cellular expression pattern of collapsin response mediator protein-2 and ubiquitin carboxy-terminal hydrolase L1 were investigated in human chronic-active MS lesions by immunohistochemistry. The observation that in multiple sclerosis lesions phosphorylated collapsin response mediator protein-2 was increased, whereas Ubiquitin carboxy-terminal hydrolase L1 was down-regulated, not only highlights the importance of these molecules in the pathology of this disease, but also illustrates the use of our approach in attempting to decipher the complex pathological processes leading to multiple sclerosis and other neurodegenerative diseases.  Further, we show that in clinicaly isolated syndrome (CIS), we could identify important molecules that could serve as an early diagnostic biomarker in MS.

Krishnakumar

Dr. Lee Hartwell Session @ Amriteshwari Hall
Aug 12 @ 8:15 pm – 9:15 pm
LeeHartwellLeland H. Hartwell Ph.D.
2001 Nobel Laureate, Physiology & Medicine

Dr. Lee Hartwell received the 2001 Nobel Prize in Physiology / Medicine for his discovery of protein molecules that control the division of cells. He was the President and Director of the Fred Hutchinson Cancer Research Center in Seattle, Washington before moving to Arizona State University’s Center for Sustainable Health.

Dr. Hartwell is also adjunct faculty at Amrita University. He spoke to the delegates at Bioquest from his office in the US, over Amrita’s e-learning platform A-View. Given below are excerpts from his address.

I would like to address the young people in the audience. I know that many of you may have come to this meeting wondering, “How can I become a successful scientist? How can I prepare myself to make a contribution in this world?”

These questions are interesting to me also.

Believe it or not, I am still trying to be a successful scientist. That may surprise you since you probably think that a Nobel laureate must have found the answers. But the problem is that the answers to these questions change with time and the answers are different today than what they were when I began my career fifty years ago. The strategy of the 1960’s doesn’t work so well anymore. What is different now?

First, what we know now is much more. For example, by 1970, no genes from any organisms were sequenced. In 2013, we have the complete sequence of the human genome. Second, not only do we know much more today, accessing that knowledge is easy. Third, obtaining new information is much faster today.

Our rich understanding of science and technology is now needed to solve many serious problems. The human population has reached the size where we are utilizing all available resource of the planet. We are utilizing all of the agricultural land, all of the water, all of the forest and fishing resources. We are also polluting the planet that we live on.

We are polluting the land with fertilizers and pesticides; the oceans with acids and the atmosphere with carbon dioxide. We are using up top soil and ground water, thereby reducing our capacity to feed ourselves. We are using up petroleum, the energy source that our entire economy is dependent on. These are problems we were largely unaware of, fifty years ago. But these are problems that must be solved in your life times.

The big question facing your generation is, how can human beings live sustainably on planet earth. Your two broad goals on sustainability are 1) leave the planet as you first found it for your future generations; don’t use up the resources and don’t pollute the planet 2) everyone deserves to have an equal share of the earth’s resources.

Income strongly determines one’s opportunities in life. Many poor people succumb to chronic diseases and unhealthy environments. This inequality undermines our ability to live sustainably. We can’t ask the poor to leave the planet as they found it if they can’t support their families. Education, healthcare, employment are essential to having a sustainable society.

How can we be a successful scientist in 2013?
1. First choose a problem to solve
2. Ask questions to understand why it is not solved
3. Collaborate with those who can help
4. Develop a solution that works in the real world

Chronic diseases are our major burden and this burden will get worse. Heart disease, diabetes, cancer, dementia and other diseases. The good news is that the chronic diseases are largely preventable and more easily curable if detected early. One question that attracts me is how can we detect disease earlier when it can be more easily cured?

Can we use our increasing knowledge in molecular biology to identify biomarkers for early disease detection?

We need to collaborate very closely with clinicians who care for patients to find out exactly where they need help.

I think if we apply our technology to important clinical questions we will actually save medical expenditure and be well on our way to making a great contribution to society.

 

Aug
13
Tue
2013
Plenary Talk: Biosensor and Single Cell Manipulation using Nanopipettes @ Amriteshwari Hall
Aug 13 @ 10:06 am – 10:49 am

NaderNader Pourmand, Ph.D.
Director, UCSC Genome Technology Center,University of California, Santa Cruz


Biosensor and Single Cell Manipulation using Nanopipettes

Approaching sub-cellular biological problems from an engineering perspective begs for the incorporation of electronic readouts. With their high sensitivity and low invasiveness, nanotechnology-based tools hold great promise for biochemical sensing and single-cell manipulation. During my talk I will discuss the incorporation of electrical measurements into nanopipette technology and present results showing the rapid and reversible response of these subcellular sensors  to different analytes such as antigens, ions and carbohydrates. In addition, I will present the development of a single-cell manipulation platform that uses a nanopipette in a scanning ion-conductive microscopy technique. We use this newly developed technology to position the nanopipette with nanoscale precision, and to inject and/or aspirate a minute amount of material to and from individual cells or organelle without comprising cell viability. Furthermore, if time permits, I will show our strategy for a new, single-cell DNA/ RNA sequencing technology that will potentially use nanopipette technology to analyze the minute amount of aspirated cellular material.